@article{CJCR3356,
author = {Pei-Hung Chang and Jen-Seng Huang},
title = {Successful rechallenge of cetuximab following severe infusion-related reactions: a case report},
journal = {Chinese Journal of Cancer Research},
volume = {26},
number = {1},
year = {2014},
keywords = {},
abstract = {Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is associated with a risk of infusion reactions, similar to other infusional agents. Although avoiding a rechallenge with cetuximab following a severe infusion reaction is preferable, this may not be an option if few other reasonable alternatives exist. We report herein a successful case of cetuximab rechallenge, carried out by extending infusion times and using saline dilution in a patient who had severe infusion reactions twice and who required continuation of treatment. Cetuximab reintroduction with saline dilution and a slower infusion rate in an intensive care setting allowed safe continuation of therapy.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/3356}
}